$TMO

Thermo Fisher Scientific and KYAN Technologies signed an MoU to collaborate on functional precision oncology for solid tumors. The work will culture patient-derived tumoroids from breast, pancreatic, ovarian and colorectal cancers using Thermo Fisher media, screen drug responses, and analyze results with KYAN’s Optim.AI platform and Thermo Fisher NGS tools (Genexus, Oncomine).

Vietnam’s Ministry of Finance National Innovation Center (NIC) plans, with Thermo Fisher Scientific, to set up a shared semiconductor and biomedical lab at NIC Hoa Lac, Hanoi, according to an MoU signed Aug. 13. The facility is intended for R&D, testing, and training. Thermo Fisher said it has about $220 billion market cap and operates in 50+ countries.

Shafer Michael D (Executive Vice President) sold 25,500 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $600.00 ($15.30M total) across 2 trades on 2026-08-11 under a Rule 10b5-1 trading plan.

Vietnam’s Deputy PM Dung said the government is prioritizing semiconductors, AI, biomedical technology and high-tech manufacturing, and plans to sign an MoU with Thermo Fisher Scientific to study a shared laboratory at the National Innovation Centre (NIC). Thermo Fisher said it wants to expand in Vietnam via infrastructure, labs and manufacturing, and provide forensic and genetic sequencing tech.

Thermo Fisher Scientific launched Thermo Scientific InstaFlux, an integrated media-on-demand enrichment workflow for food microbiology labs. The company says it can prepare media in under 30 minutes, reduce media prep labor by more than 80%, and cut water and energy use by up to 90% versus conventional methods. It supports barcode and LIMS integration and claims ISO-compliant gravimetric dispensing for buffered peptone water workflows.

Thermo Fisher Scientific said it has completed the sale of its microbiology unit to Astorg, according to the company. The update follows the firm’s stock trading snapshot and related market notes, with Thermo Fisher shares at about $600.14 and down 0.80% on the day.

Thermo Fisher Scientific (NYSE: TMO) said it completed the sale of its microbiology business to Astorg for about $1.075 billion, made up of cash and a $50 million seller note. The unit, part of Thermo Fisher’s Specialty Diagnostics segment, earned $645 million in revenue in 2025 and provides antimicrobial susceptibility testing and culture media solutions.

Thermo Fisher Scientific launched the PPD CorEvitas Vitiligo Registry to collect real-world outcomes for nonsegmental vitiligo patients in the US, using clinician and patient-reported data. The article cites 2025 revenue of $44.6B (+4%) and EPS of $17.74 (+7%), plus 2026 guidance of $46.3B to $47.2B. It also discusses related acquisitions, including an $8.8B Clario deal.

A roundup of Q2 earnings trends for major pharma and biotech firms highlights GLP-1 marketing spend, biosimilar and generic competition, and China-related risks. Eli Lilly raised Q2 marketing expenses 25% to $3.43B and lifted year-end revenue guidance to $85B-$87B. Novo Nordisk reported 5M Wegovy pill prescriptions in 30 weeks. Pfizer cut promotional costs and plans $2.5B savings (2027-29).

Abbott Laboratories (ABT) reported fiscal Q2 2026 results, with sales up 13% reported and 4.8% comparable, and raised its annual profit forecast, citing strong cancer diagnostics and medical device demand. Thermo Fisher Scientific (TMO) reported improving life sciences spending, with Life Sciences Solutions revenue up 13% and organic up 3%, plus Analytical Instruments returning to growth.